Do signatures of tumour immunity distinguish Asian and non-Asian gastric adenocarcinomas?
Analyses of >1600 GCs suggest that Asian and non-Asian GCs exhibit distinct tumour immunity signatures related to T-cell function. These differences may influence geographical differences in clinical outcome, and the design of future trials particularly in immuno-oncology.
Pioglitazone does not affect the risk of kidney cancer.